首页> 外文期刊>Vaccine >Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
【24h】

Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.

机译:源自百日咳博德特氏菌的外膜囊泡,作为针对百日咳博德特氏菌和百日咳博德特氏菌感染的脱细胞疫苗。

获取原文
获取原文并翻译 | 示例
       

摘要

Bordetella parapertussis, a close related species of B. pertussis, can also cause the disease named pertussis or whooping cough. The number of cases caused by this related pathogen has risen sustained in the last years. The widely used cellular (wP) or acellular (aP) pertussis vaccines have little or no efficacy against B. parapertussis. In an effort to devise an effective acellular vaccine against B. parapertussis infection, outer membrane vesicles (OMVs) were obtained from B. parapertussis. Proteomic analysis of the resulting OMVs, designated OMVsBpp, evidenced the presence of several surface immunogens including pertactin. The characterized OMVsBpp were used in murine B. parapertussis intranasal challenge model to examine their protective capacity when administered by systemic route. Immunized BALB/c mice were challenged with sublethal doses of B. parapertussis. Significant differences between immunized animals and the negative control group were observed (p<0.001). OMVsBpp protected against B. parapertussis infection, whereas current commercial aP vaccine showed little protection against such pathogen. More interestingly, protection induced by OMVsBpp against B. pertussis was comparable to our previously designed vaccine consisting in OMVs derived from B. pertussis (OMVsBp). For these experiments we used as a positive control the current commercial aP vaccine in high dose. As expected aP offered protection against B. pertussis in mice. Altogether the results presented here showed that the OMVs from B. parapertussis are an attractive vaccine candidate to protect against whooping cough induced by B. parapertussis but also by B. pertussis.Digital Object Identifier http://dx.doi.org/10.1016/j.vaccine.2013.08.059
机译:百日咳博德特氏杆菌是百日咳博德特氏菌的近缘种,也可能引起百日咳或百日咳。在最近几年中,由这种相关病原体引起的病例数持续上升。广泛使用的细胞(wP)或无细胞(aP)百日咳疫苗对百日咳博德特氏菌几乎没有效力。为了设计一种有效的针对百日咳博德特氏菌感染的脱细胞疫苗,从百日咳博德特氏菌中获得了外膜囊泡(OMV)。对所得的OMVs(称为OMVsBpp)进行蛋白质组学分析,证明存在多种表面免疫原,包括百日咳杆菌粘附素。表征的OMVsBpp被用于鼠百日咳博德特氏菌鼻内攻击模型中,以检查其通过全身途径给药时的保护能力。亚致死剂量的副百日咳博德特氏菌攻击免疫的BALB / c小鼠。观察到免疫动物和阴性对照组之间的显着差异(p <0.001)。 OMVsBpp可以抵抗百日咳博德特氏菌感染,而目前的商业aP疫苗几乎没有针对这种病原体的保护。更有趣的是,由OMVsBpp诱导的针对百日咳博德特氏菌的保护作用与我们先前设计的包含源自百日咳博德特氏菌的OMV(OMVsBp)的疫苗相当。对于这些实验,我们将目前市售的高剂量aP疫苗用作阳性对照。如所预期的,aP提供了针对小鼠中百日咳博德特氏菌的保护。总的来说,此处显示的结果表明,来自副百日咳杆菌的OMV是一种有吸引力的疫苗候选物,可以预防百日咳博德特氏菌和百日咳博德特氏菌引起的百日咳。数字对象标识符http://dx.doi.org/10.1016/ j.vaccine.2013.08.059

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号